Related Experiment Videos
Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry
B Saletu1, J Grünberger, L Linzmayer
1Department of Psychiatry, School of Medicine, University of Vienna, Austria.
Psychopharmacology
|January 1, 1992
Summary
Co-dergocrine mesylate (CDM) mitigated moderate hypoxia-induced brain function decline in healthy volunteers. However, higher hypoxia levels diminished these protective effects, with varying impacts on cognitive and emotional functions.
Area of Science:
- Neuroscience
- Pharmacology
- Human Physiology
Background:
- Hypoxia, or impaired cerebral metabolism due to low oxygen, significantly affects brain function and mental performance.
- Co-dergocrine mesylate (CDM) is a medication with potential cognitive-enhancing properties.
- Understanding the neuroprotective effects of CDM under hypoxic conditions is crucial for managing cognitive function.
Purpose of the Study:
- To investigate the effects of two doses of co-dergocrine mesylate (CDM) on human brain function and mental performance under experimentally induced hypoxia.
- To evaluate the dose-dependent efficacy of CDM in mitigating hypoxic hypoxidosis.
- To assess the impact of CDM on vigilance, noopsychic, and thymopsyche performance during hypoxia.
Main Methods:
- A double-blind, placebo-controlled trial involving 18 healthy volunteers.
- Experimental induction of hypoxia using fixed gas mixtures simulating altitudes of 6000m (9.8% O2) and 7000m (8.6% O2).
- Administration of placebo, 6 mg, and 9 mg of co-dergocrine mesylate (CDM) followed by assessments using blood gas analysis, EEG mapping, and psychometry.
Main Results:
- Moderate hypoxia (6000m) led to decreased PO2, increased delta and decreased alpha power in EEG, and impaired cognitive performance.
- 6 mg of CDM attenuated vigilance deterioration and improved noopsychic performance under moderate hypoxia, with effects observed between 2-6 hours.
- Higher hypoxia (7000m) reduced or abolished CDM's protective effects, while somatic complaints were mitigated dose-dependently under moderate hypoxia only.
Conclusions:
- Co-dergocrine mesylate (CDM) demonstrates a dose-dependent protective effect against moderate hypoxia-induced cognitive decline.
- The efficacy of CDM is diminished under more severe hypoxic conditions, highlighting limitations in its neuroprotective capacity.
- CDM may offer benefits in managing cognitive function during mild to moderate hypoxic stress, but further research is needed for severe hypoxia.